Research progress on the pharmacological activities of senkyunolides

Abstract

Senkyunolides are a group of phthalide molecules that exist in Umbelliferae plants, with the highest abundance in Ligusticum chuanxiong Hort, a medicinal herb with therapeutic applications in various diseases such as coronary heart disease, migraine, and rheumatism. Modern research has highlighted the anti-inflammatory, analgesic, and cardiovascular-protective properties of senkyunolides. Recently, some novel effects, such as antibacterial, anti-osteoporosis, and anti-fibrosis, have been reported for senkyunolides, indicating their diverse biological activities. In addition, because of its high bioavailability and ability to cross the blood-brain barrier (BBB), particularly exemplified by senkyunolide I (SEI), holds promise for the treatment of brain diseases. Multiple signaling pathways have been related to the pharmacological activities of senkyunolides, such as the toll-like receptor 4/nuclear factor-kappa B (NF-κB) signaling, extracellular signal-regulated kinase (ERK) pathway, p38 mitogen-activated protein kinase, and c-Jun N-terminal kinase (JNK) pathways. Here, we review the research progress on the pharmacokinetics and pharmacological effects of senkyunolides, which are promising candidates for future drug development and have significant clinical value in the treatment of various diseases.

Keywords

Ligusticum chuanxiong Hort / Pharmacokinetics / Pharmacological activities / Senkyunolides

References

[[1]] Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia 1. Beijing: China Medical Science Press; 2020.

[[2]] Li H, Hu S, Zhou Y, et al. Pharmacology progress on the main bioactive components of Ligusticum chuanxiong hort. Chin J Clin Pharmacol Ther 2018;23(11):1302-1308.

[[3]] Wei X, Zeng Y, Sun C, et al. Recent advances in natural phthalides: distribution, chemistry, and biological activities. Fitoterapia 2022;160:105223.

[[4]] Pannek J, Gach J, Boratyński F, et al. Antimicrobial activity of extracts and phthalides occurring in Apiaceae plants. Phytother Res 2018;32(8):1459-1487.

[[5]] Chen WR, Chou CC, Wang CC. Phthalides serve as potent modulators to boost fetal hemoglobin induction therapy for β-hemoglobinopathies. Blood Adv 2019;3(9):1493-1498.

[[6]] Zhang LJ, Liu JY, Yao C, et al. Research progress in pharmacological activities of Senkyunolides. Chin Pharm J 2015;50(13):1081-1084.

[[7]] Lyu J-L, Duan J-A, Tang Y-P, et al. Phthalide mono- and dimers from the radix of Angelica sinensis. Biochem Syst Ecol 2009;37(4):405-411.

[[8]] Yang Y, Feng Y, Chen H, et al. Research advance in phthalides and their biological activities. Nat Prod Res Dev 2022;34(8):1439-1453.

[[9]] Zuo A, Wang L, Xiao H, et al. Identification of the absorbed components and metabolites in rat plasma after oral administration of Rhizoma Chuanxiong decoction by HPLC-ESI-MS/MS. J Pharm Biomed Anal 2011;56(5):1046-1056.

[[10]] Liu Y, Luo Z-Q, Lyu B-R, et al. Absorption and metabolism of Chuanxiong Rhizoma decoction with multi-component sequential metabolism method. Chin J Chin Mat Med 2016;41(7):1178-1182.

[[11]] Tao S, Li H, Liu J. Metabolic profiling of ligustilide and identification of the metabolite in rat and human hepatocytes by liquid chromatography combined with high-resolution mass spectrometry. J Sep Sci 2020;43(24):4405-4413.

[[12]] He CY, Wang S, Feng Y, et al. Pharmacokinetics, tissue distribution and metabolism of senkyunolide I, a major bioactive component in Ligusticum chuanxiong Hort. (Umbelliferae). J Ethnopharmacol 2012;142(3):706-713.

[[13]] Xiong YK, Lin X, Liang S, et al. Identification of senkyunolide I metabolites in rats using ultra performance liquid chromatography/quadrupole-time-of-flight tandem mass spectrometry. J Pharm Biomed Anal 2013;81-82:178-186.

[[14]] Ma Q, Ma C, Wu F, et al. Preparation and structural determination of four metabolites of senkyunolide I in rats using ultra performance liquid chromatography/quadrupole-time-of-flight tandem mass and nuclear magnetic resonance spectra. BMC Complement Altern Med 2016;16(1):504.

[[15]] Li H, Jiang Y, Wang Y, et al. The effects of Warfarin on the pharmacokinetics of senkyunolide I in a rat model of biliary drainage after administration of Chuanxiong. Front Pharmacol 2018;9:1461.

[[16]] Li JQ, Wang JF, Li J, et al. A validated LC-MS/MS method for the determination of senkyunolide I in dog plasma and its application to a pharmacokinetic and bioavailability studies. Biomed Chromatogr 2018;32(5):e4182.

[[17]] Yan R, Lin G, Ko NL, et al. Low oral bioavailability and pharmacokinetics of senkyunolide a, a major bioactive component in Rhizoma Chuanxiong, in the rat. Ther Drug Monit 2007;29(1):49-56.

[[18]] Zhang H, Liu C, Wang M, et al. Metabolic profiling of senkyunolide A and identification of its metabolites in hepatocytes by ultra-high-performance liquid chromatography combined with diode-array detector and high-resolution mass spectrometry. Rapid Commun Mass Spectrom 2020;34(21):e8894.

[[19]] Ning Y, Pei K, Cao G, et al. Comparative study on pharmacokinetics of four active compounds in rat plasma after oral administration of raw and wine processed Chuanxiong Rhizoma. Molecules 2019;25(1):93.

[[20]] Pei K, Cao L, Cao G, et al. A reasonable evaluation of Chuanxiong Rhizoma processing with wine through comparative pharmacokinetic study of bioactive components: dominant effect on middle cerebral artery occlusion model rats. J Anal Methods Chem 2022;2022:8252038.

[[21]] Han L, Liu DL, Zeng QK, et al. The neuroprotective effects and probable mechanisms of Ligustilide and its degradative products on intracerebral hemorrhage in mice. Int Immunopharmacol 2018;63:43-57.

[[22]] Zhao B, Tang KC, Zhao Y, et al. Senkyunolide H affects cerebral ischemic injury through regulation on autophagy of neuronal cells via P13K/AKT/mTOR signaling pathway. Dis Markers 2022;2022:9211621.

[[23]] Hu Y, Duan M, Liang S, et al. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3. Brain Res 2015;1605:39-48.

[[24]] Xie J, Zhao ZZ, Li P, et al. Senkyunolide I protects against sepsis-associated encephalopathy by attenuating sleep deprivation in a murine model of cecal ligation and puncture. Oxid Med Cell Longevity 2021;2021:6647258.

[[25]] Shabab T, Khanabdali R, Moghadamtousi SZ, et al. Neuroinflammation pathways: a general review. Int J Neurosci 2017;127(7):624-633.

[[26]] Tan J, Li W, Teng Z, et al. Senkyunolide H inhibits activation of microglia and attenuates lipopolysaccharide-mediated neuroinflammation and oxidative stress in BV2 microglia cells via regulating ERK and NF-κB pathway. Kaohsiung J Med Sci 2022;38(4):378-384.

[[27]] Hu YY, Wang Y, Liang S, et al. Senkyunolide I attenuates oxygen-glucose deprivation/reoxygenation-induced inflammation in microglial cells. Brain Res 2016;1649(Pt A):123-131.

[[28]] Luo Y, Li X, Liu T, et al. Senkyunolide H protects against MPP(+)-induced apoptosis via the ROS-mediated mitogen-activated protein kinase pathway in PC12 cells. Environ Toxicol Pharmacol 2019;65:73-81.

[[29]] Gu Y, Huang P, Cheng T, et al. A multiomics and network pharmacological study reveals the neuroprotective efficacy of Fu-Fang-Dan-Zhi tablets against glutamate-induced oxidative cell death. Comput Biol Med 2022;148:105873.

[[30]] Wang M, Hayashi H, Horinokita I, et al. Neuroprotective effects of senkyunolide I against glutamate-induced cells death by attenuating JNK/caspase-3 activation and apoptosis. Biomed Pharmacother 2021;140:111696.

[[31]] Hu PY, Liu D, Zheng Q, et al. Elucidation of transport mechanism of paeoniflorin and the influence of ligustilide, senkyunolide I and senkyunolide A on paeoniflorin transport through Mdck-Mdr1 cells as blood-brain barrier in vitro model. Molecules 2016;21(3):300.

[[32]] Shuai S-Y, Liu S-S, Liu X-J, et al. Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor. J Ethnopharmacol 2022;298:115646.

[[33]] Hellinger E, Veszelka S, Tóth AE, et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 2012;82(2):340-351.

[[34]] Hashimoto Y, Greene C, Munnich A, et al. The CLDN5 gene at the blood-brain barrier in health and disease. Fluids Barriers CNS 2023;20(1):22.

[[35]] Wang Y, Peng F, Xie G, et al. Rhubarb attenuates blood-brain barrier disruption via increased zonula occludens-1 expression in a rat model of intracerebral hemorrhage. Exp Ther Med 2016;12(1):250-256.

[[36]] Liu S-S, Zheng Q, Yue P-F, et al. Effect and mechanism of phthalides from Ligusticum chuanxiong on oxygen-glucose deprivation/reperfusion-induced MDCK-MDR1 cell injury. Chin Tradit Herbal Drugs 2021;52(10):2958-2966.

[[37]] Zheng Q, Tang Y, Hu PY, et al. The influence and mechanism of ligustilide, senkyunolide I, and senkyunolide A on echinacoside transport through MDCK-MDR1 cells as blood-brain barrier in vitro model. Phytother Res 2018;32(3):426-435.

[[38]] Mahar M, Cavalli V. Intrinsic mechanisms of neuronal axon regeneration. Nat Rev Neurosci 2018;19(6):323-337.

[[39]] Doron-Mandel E, Fainzilber M, Terenzio M. Growth control mechanisms in neuronal regeneration. FEBS Lett 2015;589(14):1669-1677.

[[40]] Zheng S, L X, Yang L, et al. Study on cerebral protective effect of Senkyunolide trol mechanisms in neuronal regeneration. ion p38 MAPK signaling pathway. Tradit Chin Drug Res Clin Pharmacol 2019;30(9):1083-1087.

[[41]] Li J, Liu H, Yang Z, et al. Synergistic effects of cryptotanshinone and ssenkyunolide I in Guanxinning tablet against endogenous thrombus formation in Zebrafish. Front Pharmacol 2020;11:622787.

[[42]] Zhu M, Tang Y, Duan JA, et al. Roles of paeoniflorin and senkyunolide I in SiWu decoction on antiplatelet and anticoagulation activities. J Sep Sci 2010;33(21):3335-3340.

[[43]] Zhang K, Shen X, Yang L, et al. Exploring the Q-markers of Angelica sinensis (Oliv.) Diels of anti-platelet aggregation activity based on spectrum-effect relationships. Biomed Chromatogr 2022;36(9):e5422.

[[44]] Zhang Q, Yang YX, Li SY, et al. An ultrafiltration and high performance liquid chromatography coupled with diode array detector and mass spectrometry approach for screening and characterizing thrombin inhibitors from Rhizoma Chuanxiong. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1061-1062:421-429.

[[45]] Yang YY, Wu ZY, Xia FB, et al. Characterization of thrombin/factor Xa inhibitors in Rhizoma Chuanxiong through UPLC-MS-based multivariate statistical analysis. Chin Med 2020;15:93.

[[46]] Chan SS, Cheng TY, Lin G. Relaxation effects of ligustilide and senkyunolide A, two main constituents of Ligusticum chuanxiong, in rat isolated aorta. J Ethnopharmacol 2007;111(3):677-680.

[[47]] Lei W, Ni J, Xia X, et al. Searching for synergistic calcium antagonists and novel therapeutic regimens for coronary heart disease therapy from a Traditional Chinese Medicine, Suxiao Jiuxin Pill. J Chromatogr B Analyt Technol Biomed Life Sci 2018;1092:220-227.

[[48]] Wang S, Feng Y, Wang Y, et al. Senkyunolide Ⅰ promotes endothelial cells angiogenesis through PIGF signaling pathway. Pharm Biotechnol 2011;18(3):211-214.

[[49]] Kobayashi S, Mimura Y, Naitoh T, et al. Chemical structure-activity of cnidium rhizome-derived phthalides for the competence inhibition of proliferation in primary cultures of mouse aorta smooth muscle cells. Jpn J Pharmacol 1993;63(3):353-359.

[[50]] Kobayashi S, Mimura Y, Notoya K, et al. Antiproliferative effects of the traditional Chinese medicine shimotsu-to, its component cnidium rhizome and derived compounds on primary cultures of mouse aorta smooth muscle cells. Jpn J Pharmacol 1992;60(4):397-401.

[[51]] Araujo J, Zhang M, Yin F. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol 2012;3:119.

[[52]] Yang Q, Zhao ZZ, Xie J, et al. Senkyunolide I attenuates hepatic ischemia/reperfusion injury in mice via anti-oxidative, anti-inflammatory and anti-apoptotic pathways. Int Immunopharmacol 2021;97:107717.

[[53]] Zhu YL, Huang J, Chen XY, et al. Senkyunolide I alleviates renal ischemia-reperfusion injury by inhibiting oxidative stress, endoplasmic reticulum stress and apoptosis. Int Immunopharmacol 2022;102:108393.

[[54]] Qi H, Siu SO, Chen Y, et al. Senkyunolides reduce hydrogen peroxide-induced oxidative damage in human liver HepG2 cells via induction of heme oxygenase-1. Chem Biol Interact 2010;183(3):380-389.

[[55]] Lei W, Deng YF, Hu XY, et al. Phthalides, senkyunolide A and ligustilide, show immunomodulatory effect in improving atherosclerosis, through inhibiting AP-1 and NF-κB expression. Biomed Pharmacother 2019;117:109074.

[[56]] Jung IH, Choi JH, Jin J, et al. CD137-inducing factors from T cells and macrophages accelerate the destabilization of atherosclerotic plaques in hyperlipidemic mice. FASEB J 2014;28(11):4779-4791.

[[57]] Shao M, Lyu D, Zhou K, et al. Senkyunolide A inhibits the progression of osteoarthritis by inhibiting the NLRP3 signalling pathway. Pharm Biol 2022;60(1):535-542.

[[58]] Ningsih FN, Okuyama T, To S, et al. Comparative analysis of anti-inflammatory activity of the constituents of the rhizome of Cnidium officinale using rat hepatocytes. Biol Pharm Bull 2020;43(12):1867-1875.

[[59]] Li C, Wang P, Li M, et al. The current evidence for the treatment of sepsis with Xuebijing injection: bioactive constituents, findings of clinical studies and potential mechanisms. J Ethnopharmacol 2021;265:113301.

[[60]] Jiang M, Zhou M, Han Y, et al. Identification of NF-κB inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF. J Ethnopharmacol 2013;147(2):426-433.

[[61]] Zha YF, Xie J, Ding P, et al. Senkyunolide I protect against lung injury via inhibiting formation of neutrophil extracellular trap in a murine model of cecal ligation and puncture. Int Immunopharmacol 2021;99:107922.

[[62]] Stiller CO, Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: importance of dose-response considerations and fair play in comparative trials. J Intern Med 2022;292(4):557-574.

[[63]] Cao H, Yu R, Choi Y, et al. Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation. Pharmacol Res 2010;61(6):519-524.

[[64]] Bae KE, Choi YW, Kim ST, et al. Components of rhizome extract of Cnidium officinale Makino and their in vitro biological effects. Molecules 2011;16(10):8833-8847.

[[65]] Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care 2019;25(2 Suppl):S23-S34.

[[66]] Zhao X, Ma T, Zhang C, et al. Simultaneous determination of senkyunolide I and senkyunolide H in rat plasma by LC-MS: application to a comparative pharmacokinetic study in normal and migrainous rats after oral administration of Chuanxiong Rhizoma extract. Biomed Chromatogr 2015;29(9):1297-1303.

[[67]] Wang Y-H, Hong Y-L, Feng Y, et al. Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. Eur J Drug Metab Pharmacokinet 2012;37(2):91-97.

[[68]] Mittal M, Siddiqui MR, Tran K, et al. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 2014;20(7):1126-1167.

[[69]] DuanMu Y, Gu CC, Dong X, et al. Pharmacodynamic action of Senkyunolide Ⅰ on cortical spreading depression in migraine rats. Tradit Chin Drug Res Clin Pharmacol 2013;24(3):217-221.

[[70]] Guo L, Gong M, Wu S, et al. Identification and quantification of the quality markers and anti-migraine active components in Chuanxiong Rhizoma and Cyperi Rhizoma herbal pair based on chemometric analysis between chemical constituents and pharmacological effects. J Ethnopharmacol 2020;246:112228.

[[71]] Kim TY, Kwon HC, Lee SY, et al. Antibacterial activity of senkyunolide A isolated from Cnidium Officinale extract. J Cosmet Sci 2020;71(6):377-383.

[[72]] Chen H, Zhao Y, Qin G, et al. Antifungal effects and active components of Ligusticum chuanxiong. Molecules 2022;27(14):4589.

[[73]] Liu MM, Huang KM, Qian L, et al. Effects of bioactive constituents in the Traditional Chinese Medicinal formula Si-Wu-Tang on Nrf2 signaling and neoplastic cellular transformation. Phytomedicine 2018;40:1-9.

[[74]] Wang L-T, Chen L-R, Chen K-H. Hormone-related and drug-induced osteoporosis: a cellular and molecular overview. Int J Mol Sci 2023;24(6):5814.

[[75]] Yang D, Liu T, Jiang G, et al. Senkyunolide H attenuates osteoclastogenesis and postmenopausal osteoporosis by regulating the NF-κB, JNK and ERK signaling pathways. Biochem Biophys Res Commun 2020;533(3):510-518.

[[76]] Zheng L, C X, Yin B, et al. Effect and mechanism of senkyunolide A on renal interstitial fibrosis in unilateral ureteral obstruction rats. Chin J Surg Integr Tradit West Med 2020;26(2):237-242.

[[77]] Wang H, Bao Q, Yi H, et al. The evaluation of embryotoxicity of Ligusticum chuanxiong on mice and embryonic stem cells. J Ethnopharmacol 2019;239:111895.

[[78]] Zhang H, Han T, Yu CH, et al. Analysis of the chemical composition, acute toxicity and skin sensitivity of essential oil from rhizomes of Ligusticum chuanxiong. J Ethnopharmacol 2012;144(3):791-796.

[[79]] Wang S, Ma F, Huang L, et al. Dl-3-n-butylphthalide (NBP): a promising therapeutic agent for ischemic stroke. CNS Neurol Disord Drug Targets 2018;17(5):338-347.

[[80]] Fang Y, Wang R, Wang Q, et al. Design and synthesis of novel senkyunolide analogues as neuroprotective agents. Bioorg Med Chem Lett 2018;28(4):668-672.

[[81]] Tang F, Yan YM, Yan HL, et al. Chuanxiongdiolides R4 and R5, phthalide dimers with a complex polycyclic skeleton from the aerial parts of Ligusticum chuanxiong and their vasodilator activity. Bioorg Chem 2021;107:104523.

RIGHTS & PERMISSIONS

2023 Acupuncture and Herbal Medicine